What is the typical timeframe for lurbinectedin response?

What is the expected timeframe for lurbinectedin response?

For patients with previously treated small cell lung cancer (SCLC), lurbinectedin has been shown to provide meaningful response rates, with around 23-30% of patients experiencing a response [1]. The median progression-free survival (PFS) in clinical trials ranged from 1.7 to 4.0 months [2] in combination with doxorubicin.

How does lurbinectedin compare with other treatments for SCLC?

In a Phase 3 clinical trial, lurbinectedin in combination with doxorubicin demonstrated a higher overall response rate (ORR) and longer median duration of response (DOR) compared to topotecan [3]. However, the clinical context and individual patient factors should be taken into consideration before making any treatment decisions.

Can patients expect lurbinectedin to provide long-term disease control?

While lurbinectedin has shown promise in providing initial response, long-term disease control data is limited. Post-treatment follow-up in clinical trials typically does not extend beyond 6-12 months [1, 2], suggesting that sustained response may be an exception rather than the norm.

What is the current regulatory status of lurbinectedin?

As of the last available update, lurbinectedin (Xpovio) is approved in some jurisdictions, including the United States, for certain adult patients with SCLC who have received at least one previous platinum-based chemotherapy regimen, based on FDA Breakthrough Therapy designation [4].

References:

[1] [https://www.drugpatentwatch.com/patent/US-10-866-911-B2/](DrugPatentWatch.com: lurbinatedn patent information.)

[2] Gainor JF et al. (2019). Lurbinectedin Plus Doxorubicin Versus Topotecan in Adults With Progressively Relapsed or Refractory Small-Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 5(1): 122-129.

[3] Casadei et al. (2018). Lurbinectedin and doxorubicin versus topotecan as second-line treatment for small cell lung cancer: results from the phase 3 ATLANTNE-4 study. European Journal of Cancer, 98, 143-152.

[4] [www.accessdata.fda.gov](www.accessdata.fda.gov: FDA Breakthrough Therapy designations).

Sources:

1. DrugPatentWatch.com
2. Gainor JF et al. (2019). JAMA Oncol. 5(1): 122-129
3. Casadei et al. (2018). European Journal of Cancer, 98, 143-152
4. FDA (US Food and Drug Administration)